Updates

1st October, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Expiry and Non-Renewal of Commercial Arrangement with Bayer Pharmaceuticals Private Limited Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the commercial arrangement pursuant to which the Company provides sales and distribution support services to Bayer Pharmaceuticals Private Limited ("Bayer") is scheduled to expire on 31st December, 2026. This distribution arrangement will not be renewed beyond its current term. Accordingly, the arrangement will conclude upon its natural expiry on 31st December, 2026. The Company is working closely with Bayer to ensure a smooth and orderly transition of the activities currently undertaken under the arrangement. The arrangement primarily involved the provision of sales and distribution support services by the Company, for which the Company earned a commission-based income. The revenue attributable to this arrangement accounts for less than 5% of the Company's consolidated revenue. Further, as the arrangement is commission-based in nature, the Company does not expect the non-renewal to have a material impact on its profitability or financial position. Kindly take the above on record. Thank you. Yours faithfully, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla, Mumbai - 400070 T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com www.piramalpharma.com